专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07078389B2 Chemically modified oligonucleotide for site-directed mutagenesis 失效
公开(公告)号：US07078389B2
公开(公告)日：2006-07-18
申请号：US09783338
申请日：2001-02-14
申请人： Peter M. Glazer , Pamela A. Havre
发明人： Peter M. Glazer , Pamela A. Havre
IPC分类号： A01N43/04 , C12Q1/68
CPC分类号： C12N15/113 , C07H21/00 , C12N15/01 , C12N15/102 , C12N2310/15 , C12N2310/3511 , C12Q1/6827
摘要： A mutagenic, triplex-forming oligonucleotide and methods for use thereof wherein the oligonucleotide is chemically modified to incorporate a mutagen and forms a triple-stranded nucleic acid molecule with a specific DNA segment of a target DNA molecule. Upon formation of the triplex, the mutagen is brought into proximity with the target molecule and causes a mutation at a specific site therein. The mutation activates, inactivates or alters the activity and function of the target molecule.

2. 发明授权

US4868286A Translation inhibiting peptide 失效
标题翻译：翻译抑制肽
公开(公告)号：US4868286A
公开(公告)日：1989-09-19
申请号：US81929
申请日：1987-08-05
申请人： Graeme L. Hammond , Pamela A. Havre
发明人： Graeme L. Hammond , Pamela A. Havre
IPC分类号： C07K14/47
CPC分类号： C07K14/4703
摘要： A peptide that causes a suppression in protein synthesis by halting the translation of mRNA into protein, the peptide having a Stokes radius of less than 16 Angstroms, a molecular weight, determined by SDS-PAGE, of 17 kD (indicating that the peptide is a monomer) and an isoelectric point of 7.25. The peptide of the present invention may have therapeutic advantages in halting the proliferation of abnormal or excess protein,GOVERNMENT RIGHTSThis invention was made with United States Government support under Grant HL 24511-06 from the NIH. The United States Government has certain rights in this invention.
摘要翻译：通过停止mRNA到蛋白质的翻译而导致蛋白质合成抑制的肽，具有小于16埃的斯托克斯半径的肽，通过SDS-PAGE测定的分子量为17kD（表明肽是单体），等电点为7.25。本发明的肽可以在阻止异常或过量蛋白质的增殖，如恶性肿瘤，IHSS或半肥大中具有治疗优势。

3. 发明授权

US06210916B1 Rec 2 kinase 失效
标题翻译： Rec 2激酶
公开(公告)号：US06210916B1
公开(公告)日：2001-04-03
申请号：US09587436
申请日：2000-06-05
申请人： Pamela A. Havre , Michael C. Rice , William K. Holloman , Eric B. Kmiec
发明人： Pamela A. Havre , Michael C. Rice , William K. Holloman , Eric B. Kmiec
IPC分类号： C12Q148
CPC分类号： C12N9/1205 , C12N2799/026 , C12Q1/48
摘要： The invention includes a method of phosphorylating a serine containing substrate by incubating the substrate with ATP and an enzyme that is hsRec2 or muRec2 or a derivative thereof. The natural substrates of the kinase activity of Rec2 are the cell cycle control proteins such as p53 and cyclin E. The over expression of Rec2 is known to cause cell-cycle arrest and apoptosis and the invention discloses that these effects are kinase mediated. Accordingly, the invention provides a method of assessing antagonists and agonists of Rec2, which antagonists and agonists would have pharmacological activity. The invention further discloses that there is specific binding between hsRec2 and at least three cell cycle control proteins: p53, PCNA and cdc2.
摘要翻译：本发明包括通过用ATP孵育底物和使用hsRec2或muRec2或其衍生物的酶来磷酸化含丝氨酸的底物的方法。 Rec2的激酶活性的天然底物是细胞周期控制蛋白如p53和细胞周期蛋白E.已知Rec2的过度表达引起细胞周期阻滞和凋亡，本发明公开了这些作用是激酶介导的。因此，本发明提供了一种评估Rec2的拮抗剂和激动剂的方法，该拮抗剂和激动剂将具有药理活性。本发明还公开了hsRec2与至少三种细胞周期控制蛋白之间的特异性结合：p53，PCNA和cdc2。

4. 发明授权

US06174694B1 REC2 kinase 失效
标题翻译： REC2激酶
公开(公告)号：US06174694B1
公开(公告)日：2001-01-16
申请号：US09157603
申请日：1998-09-21
申请人： Pamela A. Havre , Michael C. Rice , William K. Holloman , Eric B. Kmiec
发明人： Pamela A. Havre , Michael C. Rice , William K. Holloman , Eric B. Kmiec
IPC分类号： C12Q148
CPC分类号： C12N9/1205 , C12N2799/026 , C12Q1/48
摘要： The invention includes a method of phosphorylating a serine containing substrate by incubating the substrate with ATP and an enzyme that is hsRec2 or muRec2 or a derivative thereof. The natural substrates of the kinase activity of Rec2 are the cell cycle control proteins such as p53 and cyclin E. The over expression of Rec2 is known to cause cell-cycle arrest and apoptosis and the invention discloses that these effects are kinase mediated. Accordingly, the invention provides a method of assessing antagonists and agonists of Rec2, which antagonists and agonists would have pharmacological activity. The invention further discloses that there is specific binding between hsRec2 and at least three cell cycle control proteins: p53, PCNA and cdc2.
摘要翻译：本发明包括通过用ATP孵育底物和使用hsRec2或muRec2或其衍生物的酶来磷酸化含丝氨酸的底物的方法。 Rec2的激酶活性的天然底物是细胞周期控制蛋白如p53和细胞周期蛋白E.已知Rec2的过度表达引起细胞周期阻滞和凋亡，本发明公开了这些作用是激酶介导的。因此，本发明提供了一种评估Rec2的拮抗剂和激动剂的方法，该拮抗剂和激动剂将具有药理活性。本发明还公开了hsRec2与至少三种细胞周期控制蛋白之间的特异性结合：p53，PCNA和cdc2。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式